Other Clinical Trial - Velusetrag for the Treatment of Chronic Intestinal

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04506593` - Indiana University Gastrointestinal Motility Diagnosis Registry
Recruiting	`NCT04193735` - Pseudo-obstruction Assessment With MRI
Active, not recruiting	`NCT04118699` - Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial	Phase 2
Completed	`NCT00793247` - Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)	Phase 2

See also

Status

Clinical Trial

Phase

Recruiting

NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry

Recruiting

NCT04193735 - Pseudo-obstruction Assessment With MRI

Active, not recruiting

NCT04118699 - Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial

Phase 2

Completed

NCT00793247 - Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05724069
Study type	Interventional
Source	Alfasigma S.p.A.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 15, 2021
Completion date	April 2023

Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms